ACE2 and COVID-19: Cytokines and direct viral infection of endothelial cells may decrease ACE2 expression on endothelial cells, leading to an increase in angiotensin II levels and activation of the kallikrein–bradykinin pathway, which promotes coagulation, inflammation, oxidative stress, and permeability in patients with COVID-19.